Patients
Step Pharma is focused on bringing dencatistat to the patients who need it most. Step Pharma is running clinical trials in blood cancers and solid tumours.
Clinical trials in essential thrombocythaemia will start in 2025.
These will test the safety and efficacy of dencatistat in patients who have not responded to or experienced side effects from currently available treatments.
Dencatistat has entered clinical trials for the treatment of blood cancers where dencatistat could form the backbone of various treatment regimens with the potential for accelerated approval from a single arm phase 2 study. Dencatistat (STP938) is in clinical trials for the treatment of solid tumours with an initial focus on ovarian cancer and with the potential to become a therapy for multiple solid tumour types based on biomarker selection for loss of CTPS2.
Dencatistat will enter clinical trials for the treatment of essential thrombocythaemia in 1H25.
Find information about our clinical trials at clinicaltrials.gov
Step Pharma
15 rue Louis et Auguste Lumière
Technoparc du Pays-de-Gex
01630 Saint-Genis-Pouilly
France
